{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:52:37Z","timestamp":1774896757592,"version":"3.50.1"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl. 5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2314,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Five oral agents have been approved for the treatment of chronic hepatitis B, ranging in virological potency, clinical efficacy, barrier to resistance, and side-effect profile. The degree of histological, biochemical, and serological improvement with therapy generally corresponds to the degree of suppression of serum hepatitis B virus (HBV) DNA achieved with therapy. Conversely, for agents with a low barrier to resistance, the profundity of HBV DNA suppression in individual patients correlates inversely with the likelihood of resistance. The durability of hepatitis B e antigen (HBeAg) responses after a consolidation period of an additional 6\u201312 months of therapy is \u02dc80% in western populations, lower in Asian populations. Loss of hepatitis B surface antigen (HBsAg) during a year of oral-agent therapy is limited, except with the most potent agents, but extending therapy for a second year and beyond can yield frequencies of HBsAg responses close to those reported in trials of interferon-based therapy. The oral agents are approved for 1\u20132 years of therapy, but treatment is continued indefinitely in the majority of patients (except for the \u02dc20% of patients who are HBeAg-reactive who achieve a durable HBeAg response). HBeAg responses and virological\/biochemical benefit continue to be maintained and to increase with continued therapy beyond the first year. Data continue to accumulate supporting the link between long-term HBV DNA suppression and reduction in hepatic fibrosis, hepatic decompensation, and liver-related mortality. All the benefits of a single year of injectable peginterferon therapy can be achieved with the newer, low-resistance oral agents continued beyond the first year, without interferon side effects. Future studies are needed to develop drug regimens that are even more effective in achieving clinical endpoints, that are not hampered by resistance, and that are more confined in treatment duration but are more durable. (Hepatology 2009;49:S112\u2013S121.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22920","type":"journal-article","created":{"date-parts":[[2010,7,5]],"date-time":"2010-07-05T12:31:41Z","timestamp":1278333101000},"page":"S112-S121","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":90,"title":["Benefits and risks of nucleoside analog therapy for hepatitis B #"],"prefix":"10.1097","volume":"49","author":[{"given":"Jules L.","family":"Dienstag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-14-20241201","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A oneyear trial of lamivudine for chronic hepatitis B.","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-14-20241201","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States.","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-14-20241201","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B.","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"R4-14-20241201","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigennegative chronic hepatitis B.","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-14-20241201","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAgpositive chronic hepatitis B.","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-14-20241201","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAgnegative chronic hepatitis B.","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-14-20241201","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B.","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"R8-14-20241201","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"R9-14-20241201","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cgh.2007.05.004","article-title":"Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.","volume":"5","author":"Keeffe","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R10-14-20241201","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/hep.510300427","article-title":"Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy.","volume":"30","author":"Dienstag","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R11-14-20241201","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/jhep.2003.50117","article-title":"Durability of response after lamivudine treatment of chronic hepatitis B.","volume":"37","author":"Dienstag","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R12-14-20241201","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0168-8278(03)00394-5","article-title":"Longterm additional lamivudine therapy enhances durability of lamivudineinduced HBeAg loss: a prospective study.","volume":"39","author":"Ryu","year":"2003","journal-title":"J Hepatol"},{"key":"R13-14-20241201","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAgpositive chronic hepatitis B.","volume":"133","author":"Gish","year":"2007","journal-title":"Gastroenterology"},{"key":"R14-14-20241201","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/gast.2003.50013","article-title":"Histological outcome during longterm lamivudine therapy.","volume":"124","author":"Dienstag","year":"2003","journal-title":"Gastroenterology"},{"key":"R15-14-20241201","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0168-8278(00)80371-2","article-title":"Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection.","volume":"33","author":"Yao","year":"2000","journal-title":"J Hepatol"},{"key":"R16-14-20241201","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease.","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"R17-14-20241201","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","article-title":"Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.","volume":"34","author":"Yao","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R18-14-20241201","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/hep.510290321","article-title":"Efficacy of lamivudine in patients with hepatitis B e antigennegativehepatitis B virus DNApositive (precore mutant) chronic hepatitis B.","volume":"29","author":"Tassopoulos","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R19-14-20241201","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0168-8278(01)00218-5","article-title":"Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.","volume":"35","author":"Kweon","year":"2001","journal-title":"J Hepatol"},{"key":"R20-14-20241201","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1542-3565(04)00066-7","article-title":"Reversibility of cirrhosis in chronic hepatitis B.","volume":"2","author":"Malekzadeh","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl","key":"R21-14-20241201","first-page":"706A","article-title":"Longterm entecavir therapy results in reversal of fibrosiscirrhosis and continued histologic improvement in patients with HBeAg() and () chronic hepatitis B: Results from studies ETV022, 027 and 901. Abstract.","volume":"48","author":"Liaw","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R22-14-20241201","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jlts.2002.32983","article-title":"Effect of lamivudine treatment on survival in 309 North American patients awaiting liver transplantation for chronic hepatitis B.","volume":"8","author":"Fontana","year":"2002","journal-title":"Liver Transpl"},{"issue":"Suppl","key":"R23-14-20241201","first-page":"238A","article-title":"Decline in the need for liver transplantation for end stage liver disease secondary to hepatitis B in the US. Abstract.","volume":"46","author":"Kim","year":"2007","journal-title":"HEPATOLOGY"},{"issue":"Suppl","key":"R24-14-20241201","first-page":"717A","article-title":"The potential impact of longterm nucleoside therapy on the mortality and morbidity of high viremic chronic hepatitis B. Abstract.","volume":"48","author":"Toy","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R25-14-20241201","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1440-1746.2004.03428.x","article-title":"Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.","volume":"19","author":"Chang","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"R26-14-20241201","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/gast.2000.8559","article-title":"Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.","volume":"119","author":"Liaw","year":"2000","journal-title":"Gastroenterology"},{"key":"R27-14-20241201","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.","volume":"33","author":"Leung","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R29-14-20241201","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/hep.510290507","article-title":"Multicenter study of lamivudine therapy for hepatitis B after liver transplantation.","volume":"29","author":"Perrillo","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R30-14-20241201","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.gastro.2003.10.050","article-title":"Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.","volume":"126","author":"Perrillo","year":"2004","journal-title":"Gastroenterology"},{"key":"R31-14-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.gastro.2003.10.051","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudineresistant chronic hepatitis B.","volume":"126","author":"Peters","year":"2004","journal-title":"Gastroenterology"},{"key":"R32-14-20241201","first-page":"1419","article-title":"Adefovir dipivoxil therapy for lamivudineresistant hepatitis B in pre and postliver transplantation patients.","volume":"38","author":"Schiff","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R33-14-20241201","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Longterm therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years.","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"R34-14-20241201","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Longterm therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B.","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Engl J Med"},{"key":"R35-14-20241201","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2005.10.018","article-title":"Virologic response and resistance to adefovir in patients with chronic hepatitis B.","volume":"44","author":"Fung","year":"2006","journal-title":"J Hepatol"},{"key":"R36-14-20241201","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudinerefractory, HBeAgpositive chronic hepatitis B.","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"},{"key":"R37-14-20241201","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2Year GLOBE Trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B.","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"R38-14-20241201","first-page":"376A","article-title":"Two year tenofovir fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAgpositive patients with chronic hepatitiis B (study 103), preliminary report. Abstract.","volume":"48","author":"Heathcote","year":"2008","journal-title":"HEPATOLOGY"},{"issue":"Suppl","key":"R39-14-20241201","first-page":"745A","article-title":"Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300 mg qd. Abstract.","volume":"48","author":"SnowLampart","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R40-14-20241201","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1542-3565(04)00017-5","article-title":"Tenofovir disoproxil fumarate for the treatment of lamivudineresistant hepatitis B.","volume":"2","author":"Kuo","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R41-14-20241201","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.21253","article-title":"Tenofovir for patients with lamivudineresistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.","volume":"44","author":"van Bommel","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R42-14-20241201","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.166.1.49","article-title":"A doubleblind placebocontrolled study of emtricitabine in chronic hepatitis B.","volume":"166","author":"Lim","year":"2006","journal-title":"Arch Intern Med"},{"issue":"Suppl","key":"R43-14-20241201","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1002\/hep.22921","article-title":"Benefits and risks of combination therapy for hepatitis B.","volume":"49","author":"Terrault","year":"2009","journal-title":"HEPATOLOGY"},{"key":"R44-14-20241201","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.21629","article-title":"Twentyfourweek clevudine therapy showed potent and sustained antiviral activity in HBeAgpositive chronic hepatitis B.","volume":"45","author":"Yoo","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R45-14-20241201","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2893.2006.00775.x","article-title":"Quantitative analysis of HBV cccDNA from clinical specimens: Correlation with clinical and virological response during antiviral therapy.","volume":"14","author":"Bourne","year":"2007","journal-title":"J Viral Hepat"},{"issue":"Suppl","key":"R46-14-20241201","first-page":"724A","article-title":"Lamivudine withdrawal in chronic hepatitis B patients after achieving effective maintained virologic suppression. Abstract.","volume":"48","author":"Hsu","year":"2008","journal-title":"HEPATOLOGY"},{"issue":"Suppl","key":"R47-14-20241201","first-page":"222A","article-title":"Twoyear results from the GLOBE Trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT vs. lamivudine. Abstract.","volume":"44","author":"Lai","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R48-14-20241201","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon alfa2a, lamivudine, and the combination for HBeAgpositive chronic hepatitis B.","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"R49-14-20241201","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa2a alone, lamivudine alone, and the two in combination in patients with HBeAgnegative chronic hepatitis B.","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"R50-14-20241201","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1478-3231.2008.01696.x","article-title":"Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha2a.","volume":"28","author":"Marcellin","year":"2008","journal-title":"Liver Int"},{"key":"R51-14-20241201","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-114-8-629","article-title":"Longterm remission of chronic hepatitis B after alphainterferon therapy.","volume":"114","author":"Korenman","year":"1991","journal-title":"Ann Intern Med"},{"key":"R52-14-20241201","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510280430","article-title":"10year followup after interferonalpha therapy for chronic hepatitis C.","volume":"28","author":"Lau","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R53-14-20241201","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"R54-14-20241201","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"R55-14-20241201","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.gastro.2005.05.053","article-title":"A 1year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigenpositive chronic hepatitis B.","volume":"129","author":"Lai","year":"2005","journal-title":"Gastroenterology"},{"key":"R56-14-20241201","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa2b alone or in combination with lamivudine for HBeAgpositive chronic hepatitis B: a randomised trial.","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"R57-14-20241201","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B.","volume":"45","author":"Lok","year":"2007","journal-title":"HEPATOLOGY"},{"issue":"suppl","key":"R58-14-20241201","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1002\/hep.22885","article-title":"Side effects of longterm oral antiviral therapy for hepatitis B.","volume":"49","author":"Fontana","year":"2009","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22920","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:10:56Z","timestamp":1733058656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200905001-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":57,"journal-issue":{"issue":"Suppl. 5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22920","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}